REFERENCES
1. Ye N, Ding Y, Wild C, Shen Q, Zhou J. Small molecule inhibitors targeting activator protein 1 (AP-1). J Med Chem 2014;57:6930-48.
2. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003;2:554-65.
4. Bejjani F, Evanno E, Zibara K, Piechaczyk M, Jariel-Encontre I. The AP-1 transcriptional complex: local switch or remote command? Biochim Biophys Acta Rev Cancer 2019;1872:11-23.
5. Brennan A, Leech JT, Kad NM, Mason JM. Selective antagonism of cJun for cancer therapy. J Exp Clin Cancer Res 2020;39:184.
6. Bhosale PB, Kim HH, Abusaliya A, et al. Structural and functional properties of activator protein-1 in cancer and inflammation. Evid Based Complement Alternat Med 2022;2022:9797929.
8. Eferl R, Ricci R, Kenner L, et al. Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003;112:181-92.
9. Schulien I, Hockenjos B, Schmitt-Graeff A, et al. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression. Cell Death Differ 2019;26:1688-99.
10. Videla LA, Tapia G, Rodrigo R, et al. Liver NF-kappaB and AP-1 DNA binding in obese patients. Obesity 2009;17:973-9.
11. Min L, Ji Y, Bakiri L, et al. Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol 2012;14:1203-11.
12. Fiorentino F, Carafa V, Favale G, Altucci L, Mai A, Rotili D. The two-faced role of SIRT6 in cancer. Cancers 2021;13:1156.
13. Dorn C, Engelmann JC, Saugspier M, et al. Increased expression of c-Jun in nonalcoholic fatty liver disease. Lab Invest 2014;94:394-408.
14. Lau TYH, Xiao J, Liong EC, Liao L, Leung TM, et al. Hepatic response to chronic hypoxia in experimental rat model through HIF-1 alpha, activator protein-1 and NF-kappa B. Histol Histopatho 2013;28:463-71.
15. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev 2006;17:463-74.
16. Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 2008;27:103-18.
17. Syn WK, Choi SS, Liaskou E, et al. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis. Hepatology 2011;53:106-15.
18. Kireva T, Erhardt A, Tiegs G, et al. Transcription factor Fra-1 induces cholangitis and liver fibrosis. Hepatology 2011;53:1259-69.
19. Hasenfuss SC, Bakiri L, Thomsen MK, Hamacher R, Wagner EF. Activator protein 1 transcription factor Fos-related antigen 1 (Fra-1) is dispensable for murine liver fibrosis, but modulates xenobiotic metabolism. Hepatology 2014;59:261-73.
20. Chen H, Tan H, Wan J, et al. PPAR-γ signaling in nonalcoholic fatty liver disease: pathogenesis and therapeutic targets. Pharmacol Ther 2023;245:108391.
21. Hasenfuss SC, Bakiri L, Thomsen MK, Williams EG, Auwerx J, Wagner EF. Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers. Cell Metab 2014;19:84-95.
22. Wu Q, Wu W, Fu B, Shi L, Wang X, Kuca K. JNK signaling in cancer cell survival. Med Res Rev 2019;39:2082-104.
23. Schattenberg JM, Singh R, Wang Y, et al. JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology 2006;43:163-72.
24. Steensels S, Qiao J, Ersoy BA. Transcriptional regulation in non-alcoholic fatty liver disease. Metabolites 2020;10:283.
25. Johnson R, Spiegelman B, Hanahan D, Wisdom R. Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 1996;16:4504-11.
26. Talotta F, Mega T, Bossis G, et al. Heterodimerization with Fra-1 cooperates with the ERK pathway to stabilize c-Jun in response to the RAS oncoprotein. Oncogene 2010;29:4732-40.
27. Delire B, Stärkel P. The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. Eur J Clin Invest 2015;45:609-23.
28. Singh R, Wang Y, Xiang Y, Tanaka KE, Gaarde WA, Czaja MJ. Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance. Hepatology 2009;49:87-96.
29. Czaja MJ. JNK regulation of hepatic manifestations of the metabolic syndrome. Trends Endocrinol Metab 2010;21:707-13.
30. Cho SS, Yang JH, Lee JH, et al. Ferroptosis contribute to hepatic stellate cell activation and liver fibrogenesis. Free Radic Biol Med 2022;193:620-37.
31. Roeb E. Matrix metalloproteinases and liver fibrosis (translational aspects). Matrix Biol 2018;68-69:463-73.
32. Xu H, Zhang S, Pan X, et al. TIMP-1 expression induced by IL-32 is mediated through activation of AP-1 signal pathway. Int Immunopharmacol 2016;38:233-7.
33. Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 2018;69:927-47.
34. Zhang J, Guo J, Yang N, Huang Y, Hu T, Rao C. Endoplasmic reticulum stress-mediated cell death in liver injury. Cell Death Dis 2022;13:1051.
35. Sharma RS, Harrison DJ, Kisielewski D, et al. Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-related factor 2). Cell Mol Gastroenterol Hepatol 2018;5:367-98.
36. Olivares S, Green RM, Henkel AS. Endoplasmic reticulum stress activates the hepatic activator protein 1 complex via mitogen activated protein kinase-dependent signaling pathways. PLoS One 2014;9:e103828.
37. Zahra M, Azzazy H, Moustafa A. Transcriptional regulatory networks in hepatitis C virus-induced hepatocellular carcinoma. Sci Rep 2018;8:14234.
38. Kato N, Yoshida H, Ono-Nita SK, et al. Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer. Hepatology 2000;32:405-12.
39. Trierweiler C, Hockenjos B, Zatloukal K, et al. The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice. Cell Death Differ 2016;23:576-82.
40. Tsutsumi T, Suzuki T, Moriya K, et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 2002;304:415-24.
41. Ren JH, Tao Y, Zhang ZZ, et al. Sirtuin 1 regulates hepatitis B virus transcription and replication by targeting transcription factor AP-1. J Virol 2014;88:2442-51.
42. Tanaka Y, Kanai F, Ichimura T, et al. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene 2006;25:633-42.
43. Hayashi M, Deng L, Chen M, et al. Interaction of the hepatitis B virus X protein with the lysine methyltransferase SET and MYND domain-containing 3 induces activator protein 1 activation. Microbiol Immunol 2016;60:17-25.
44. Kong GY, Zhang JP, Zhang S, Shan CL, Ye LH, Zhang XD. Hepatitis B virus X protein promotes hepatoma cell proliferation via upregulation of MEKK2. Acta Pharmacol Sin 2011;32:1173-80.
45. Cho HK, Kim SY, Kyaw YY, et al. HBx induces the proliferation of hepatocellular carcinoma cells via AP1 over-expressed as a result of ER stress. Biochem J 2015;466:115-21.
46. Junli Z, Shuhan W, Yajuan Z, Xiaoling D, Jiahuan L, Keshu X. The role and mechanism of CREBH regulating SIRT3 in metabolic associated fatty liver disease. Life Sci 2022;306:120838.
47. Wang CH, Jiang TC, Qiang WM, et al. Activator protein-1 is a novel regulator of mesencephalic astrocyte-derived neurotrophic factor transcription. Mol Med Rep 2018;18:5765-74.
48. Deng L, Liang Y, Ariffianto A, et al. Hepatitis C virus-induced ROS/JNK signaling pathway activates the E3 ubiquitin ligase itch to promote the release of HCV particles via polyubiquitylation of VPS4A. J Virol 2022;96:e0181121.
49. Ariffianto A, Deng L, Harada S, Liang Y, Matsui C, et al. Transcription factor JunB suppresses hepatitis C virus replication. Kobe J Med Sci 2023;69:E86-95.
52. Ameyar M, Wisniewska M, Weitzman JB. A role for AP-1 in apoptosis: the case for and against. Biochimie 2003;85:747-52.
53. Stepniak E, Ricci R, Eferl R, et al. C-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. Gene Dev 2006;20:2306-14.
54. Moya IM, Halder G. Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol 2019;20:211-26.
55. Zhang S, Zhou D. Role of the transcriptional coactivators YAP/TAZ in liver cancer. Curr Opin Cell Biol 2019;61:64-71.
56. Zanconato F, Forcato M, Battilana G, et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nat Cell Biol 2015;17:1218-27.
57. Koo JH, Plouffe SW, Meng Z, et al. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth. Genes Dev 2020;34:72-86.
58. Pawlonka J, Rak B, Ambroziak U. The regulation of cyclin D promoters - review. Cancer Treat Res Commun 2021;27:100338.
59. Núñez KG, Gonzalez-Rosario J, Thevenot PT, Cohen AJ. Cyclin D1 in the liver: role of noncanonical signaling in liver steatosis and hormone regulation. Ochsner J 2017;17:56-65.
60. Deane NG, Parker MA, Aramandla R, et al. Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. Cancer Res 2001;61:5389-95.
61. Che Y, Ye F, Xu R, et al. Co-expression of XIAP and cyclin D1 complex correlates with a poor prognosis in patients with hepatocellular carcinoma. Am J Pathol 2012;180:1798-807.
62. Liu Z, Yan R, Al-Salman A, et al. Epidermal growth factor induces tumour marker AKR1B10 expression through activator protein-1 signalling in hepatocellular carcinoma cells. Biochem J 2012;442:273-82.
63. DiStefano JK, Davis B. Diagnostic and prognostic potential of AKR1B10 in human hepatocellular carcinoma. Cancers 2019;11:486.
64. Wang YY, Qi LN, Zhong JH, et al. High expression of AKR1B10 predicts low risk of early tumor recurrence in patients with hepatitis B virus-related hepatocellular carcinoma. Sci Rep 2017;7:42199.
65. Geng N, Jin Y, Li Y, Zhu S, Bai H. AKR1B10 inhibitor epalrestat facilitates sorafenib-induced apoptosis and autophagy via targeting the mTOR pathway in hepatocellular carcinoma. Int J Med Sci 2020;17:1246-56.
66. Li Q, Liu G, Shao D, et al. Mucin1 mediates autocrine transforming growth factor beta signaling through activating the c-Jun N-terminal kinase/activator protein 1 pathway in human hepatocellular carcinoma cells. Int J Biochem Cell Biol 2015;59:116-25.
67. Tu S, Huang W, Huang C, Luo Z, Yan X. Contextual regulation of TGF-β signaling in liver cancer. Cells 2019;8:1235.
68. Han D, Yang P, Qin B, et al. Upregulation of Nogo-B by hypoxia inducible factor-1 and activator protein-1 in hepatocellular carcinoma. Cancer Sci 2021;112:2728-38.
69. Rao J, Cheng F, Zhou H, et al. Nogo-B is a key mediator of hepatic ischemia and reperfusion injury. Redox Biol 2020;37:101745.
70. Dong C, Zhao B, Long F, et al. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein. Oncotarget 2016;7:8850-65.
71. Dong C, Liu Y, Jiang K, et al. The Nogo-B receptor promotes human hepatocellular carcinoma cell growth via the Akt signal pathway. J Cell Biochem 2018;119:7738-46.
72. Bakiri L, Hasenfuss SC, Guío-Carrión A, Thomsen MK, Hasselblatt P, Wagner EF. Liver cancer development driven by the AP-1/c-Jun~Fra-2 dimer through c-Myc. Proc Natl Acad Sci U S A 2024;121:e2404188121.
73. Maulik N, Goswami S, Galang N, Das DK. Differential regulation of Bcl-2, AP-1 and NF-kappaB on cardiomyocyte apoptosis during myocardial ischemic stress adaptation. FEBS Lett 1999;443:331-6.
74. Takeuchi K, Motoda Y, Ito F. Role of transcription factor activator protein 1 (AP1) in epidermal growth factor-mediated protection against apoptosis induced by a DNA-damaging agent. FEBS J 2006;273:3743-55.
75. Qiao Y, He H, Jonsson P, Sinha I, Zhao C, Dahlman-Wright K. AP-1 is a key regulator of proinflammatory cytokine TNFα-mediated triple-negative breast cancer progression. J Biol Chem 2016;291:18309.
76. Jang J, Hunto ST, Kim JW, Lee HP, Kim HG, Cho JY. Anti-inflammatory activities of an anti-histamine drug, loratadine, by suppressing TAK1 in AP-1 pathway. Int J Mol Sci 2022;23:3986.
77. Kyriakis JM. Activation of the AP-1 transcription factor by inflammatory cytokines of the TNF family. Gene Exp 1999;7:217-31.
78. Thomsen MK, Bakiri L, Hasenfuss SC, Hamacher R, Martinez L, Wagner EF. JUNB/AP-1 controls IFN-γ during inflammatory liver disease. J Clin Invest 2013;123:5258-68.
79. Hasselblatt P, Rath M, Komnenovic V, Zatloukal K, Wagner EF. Hepatocyte survival in acute hepatitis is due to c-Jun/AP-1-dependent expression of inducible nitric oxide synthase. Proc Natl Acad Sci U S A 2007;104:17105-10.
80. Zhuo B, Zhang Q, Xie T, et al. Integrative epigenetic analysis reveals AP-1 promotes activation of tumor-infiltrating regulatory T cells in HCC. Cell Mol Life Sci 2023;80:103.
81. Pinter M, Scheiner B, Pinato DJ. Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice. Lancet Gastroenterol Hepatol 2023;8:760-70.
82. Doorn DJ, Takkenberg RB, Klümpen HJ. Immune checkpoint inhibitors in hepatocellular carcinoma: an overview. Pharmaceuticals 2020;14:3.
83. Venkatraman S, Meller J, Hongeng S, Tohtong R, Chutipongtanate S. Transcriptional regulation of cancer immune checkpoints: emerging strategies for immunotherapy. Vaccines 2020;8:735.
84. Xiao G, Deng A, Liu H, Ge G, Liu X. Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1. Proc Natl Acad Sci U S A 2012;109:15419-24.
85. You X, Liu F, Binder M, et al. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood 2022;139:1066-79.
86. Luo B, Zhang S, Tan D, Yu X, Lin J, Wang M. Anlotinib benefits the αPDL1 immunotherapy by activating ROS/JNK/AP-1 pathway to upregulate PDL1 expression in colorectal cancer. Oxid Med Cell Longev 2022;2022:8965903.
87. Yu P, Wei H, Li K, et al. The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun. J Exp Clin Cancer Res 2022;41:346.
88. Hsiang CY, Wu SL, Chen JC, et al. Acetaldehyde induces matrix metalloproteinase-9 gene expression via nuclear factor-kappaB and activator protein 1 signaling pathways in human hepatocellular carcinoma cells: association with the invasive potential. Toxicol Lett 2007;171:78-86.
89. Arii S, Mise M, Harada T, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996;24:316-22.
90. Nart D, Yaman B, Yilmaz F, Zeytunlu M, Karasu Z, Kiliç M. Expression of matrix metalloproteinase-9 in predicting prognosis of hepatocellular carcinoma after liver transplantation. Liver Transpl 2010;16:621-30.
91. Pan MH, Chiou YS, Chen WJ, Wang JM, Badmaev V, Ho CT. Pterostilbene inhibited tumor invasion via suppressing multiple signal transduction pathways in human hepatocellular carcinoma cells. Carcinogenesis 2009;30:1234-42.
92. Lee KH, Yeh MH, Kao ST, et al. The inhibitory effect of hesperidin on tumor cell invasiveness occurs via suppression of activator protein 1 and nuclear factor-kappaB in human hepatocellular carcinoma cells. Toxicol Lett 2010;194:42-9.
93. Yu MH, Lee SO. Hydroquinone stimulates cell invasion through activator protein-1-dependent induction of MMP-9 in HepG2 human hepatoma cells. Food Chem Toxicol 2016;89:120-5.
94. Cho SB, Park YL, Park SJ, et al. KITENIN is associated with activation of AP-1 target genes via MAPK cascades signaling in human hepatocellular carcinoma progression. Oncol Res 2011;19:115-23.
95. Sugioka Y, Watanabe T, Inagaki Y, et al. c-Jun NH2-terminal kinase pathway is involved in constitutive matrix metalloproteinase-1 expression in a hepatocellular carcinoma-derived cell line. Int J Cancer 2004;109:867-74.
96. Yoon JH, Choi YJ, Lee SG. Ginsenoside Rh1 suppresses matrix metalloproteinase-1 expression through inhibition of activator protein-1 and mitogen-activated protein kinase signaling pathway in human hepatocellular carcinoma cells. Eur J Pharmacol 2012;679:24-33.
97. Geervliet E, Bansal R. Matrix metalloproteinases as potential biomarkers and therapeutic targets in liver diseases. Cells 2020;9:1212.
98. Rhee H, Kim HY, Choi JH, et al. Keratin 19 expression in hepatocellular carcinoma is regulated by fibroblast-derived HGF via a MET-ERK1/2-AP1 and SP1 axis. Cancer Res 2018;78:1619-31.
99. Zhu Q, Wang Z, Hu Y, et al. miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep 2012;27:1660-8.
100. Liu JJ, Lin XJ, Yang XJ, et al. A novel AP-1/miR-101 regulatory feedback loop and its implication in the migration and invasion of hepatoma cells. Nucleic Acids Res 2014;42:12041-51.
101. Xian L, Xiong Y, Qin L, et al. Jun/Fos promotes migration and invasion of hepatocellular carcinoma cells by enhancing BORIS promoter activity. Int J Biochem Cell Biol 2024;169:106540.
102. Liu Y, Wang B, Cheng Y, et al. ASIC1 promotes migration and invasion of hepatocellular carcinoma via the PRKACA/AP-1 signaling pathway. Carcinogenesis 2024;45:399-408.
103. Catar R, Witowski J, Wagner P, et al. The proto-oncogene c-Fos transcriptionally regulates VEGF production during peritoneal inflammation. Kidney Int 2013;84:1119-28.
104. Ji L, Zheng Z, Shi L, Huang Y, Lu B, Wang Z. Andrographolide decreased VEGFD expression in hepatoma cancer cells by inducing ubiquitin/proteasome-mediated cFos protein degradation. Biochim Biophys Acta 2015;1850:750-8.
105. Cai H, Saiyin H, Liu X, et al. Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma. Mol Oncol 2018;12:2042-54.
106. Li YK, Xie YJ, Wu DC, Long SL, Tang S, Mo ZC. Nogo-B receptor in relevant carcinoma: current achievements, challenges and aims (review). Int J Oncol 2018;53:1827-35.
107. Acun T, Doberstein N, Habermann JK, et al. HLJ1 (DNAJB4) gene is a novel biomarker candidate in breast cancer. OMICS 2017;21:257-65.
108. Chen CH, Chang WH, Su KY, et al. HLJ1 is an endogenous Src inhibitor suppressing cancer progression through dual mechanisms. Oncogene 2016;35:5674-85.
109. Wang CC, Tsai MF, Dai TH, et al. Synergistic activation of the tumor suppressor, HLJ1, by the transcription factors YY1 and activator protein 1. Cancer Res 2007;67:4816-26.
110. Martínez-Zamudio RI, Roux PF, de Freitas JANLF, et al. AP-1 imprints a reversible transcriptional programme of senescent cells. Nat Cell Biol 2020;22:842-55.
111. Wang Y, Liu L, Song Y, Yu X, Deng H. Unveiling E2F4, TEAD1 and AP-1 as regulatory transcription factors of the replicative senescence program by multi-omics analysis. Protein Cell 2022;13:742-59.
112. Jachim SK, Zhong J, Ordog T, et al. BMAL1 modulates senescence programming via AP-1. Aging 2023;15:9984-10009.
113. Han R, Li L, Ugalde AP, et al. Functional CRISPR screen identifies AP1-associated enhancer regulating FOXF1 to modulate oncogene-induced senescence. Genome Biol 2018;19:118.
114. Dabrowska M, Uram L, Dabrowski M, Sikora E. Antigen presentation capability and AP-1 activation accompany methotrexate-induced colon cancer cell senescence in the context of aberrant β-catenin signaling. Mech Ageing Dev 2021;197:111517.
115. Bu X, Le C, Jia F, et al. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biol Ther 2008;7:392-6.
116. Yogev O, Anzi S, Inoue K, Shaulian E. Induction of transcriptionally active Jun proteins regulates drug-induced senescence. J Biol Chem 2006;281:34475-83.
117. Liu P, Kimmoun E, Legrand A, et al. Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 2002;37:63-71.
118. Chen YL, Chan SH, Lin PY, Chu PY. The expression of a tumor suppressor gene JDP2 and its prognostic value in hepatocellular carcinoma patients. Hum Pathol 2017;63:212-6.
119. Bitton-Worms K, Pikarsky E, Aronheim A. The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice. Mol Cancer 2010;9:54.
120. Daschner PJ, Ciolino HP, Plouzek CA, Yeh GC. Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 1999;53:229-40.
121. Wang Y, Wan GH, Wu YM, et al. AP-1 confers resistance to anti-cancer therapy by activating XIAP. Oncotarget 2018;9:14124-37.
122. Tang W, Chen Z, Zhang W, et al. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 2020;5:87.
123. Cabral LKD, Tiribelli C, Sukowati CHC. Sorafenib resistance in hepatocellular carcinoma: the relevance of genetic heterogeneity. Cancers 2020;12:1576.
124. Cheng BY, Lau EY, Leung HW, et al. IRAK1 augments cancer stemness and drug resistance via the AP-1/AKR1B10 signaling cascade in hepatocellular carcinoma. Cancer Res 2018;78:2332-42.
125. Yan D, Yan X, Dai X, et al. Activation of AKT/AP1/FoxM1 signaling confers sorafenib resistance to liver cancer cells. Oncol Rep 2019;42:785-96.
126. Song D, Lian Y, Zhang L. The potential of activator protein 1 (AP-1) in cancer targeted therapy. Front Immunol 2023;14:1224892.
127. Kamide D, Yamashita T, Araki K, et al. Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model. Cancer Sci 2016;107:666-73.
128. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H. Inhibition of activator protein 1 activity by berberine in human hepatoma cells. Planta Med 1999;65:381-3.
129. Tang S, Zhang F, Li J, et al. The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib. Chem Biol Interact 2023;384:110687.
130. Tewari D, Nabavi SF, Nabavi SM, et al. Targeting activator protein 1 signaling pathway by bioactive natural agents: possible therapeutic strategy for cancer prevention and intervention. Pharmacol Res 2018;128:366-75.
131. Li XJ, Li QL, Ju LG, et al. Deficiency of histone methyltransferase SET domain-containing 2 in liver leads to abnormal lipid metabolism and HCC. Hepatology 2021;73:1797-815.
132. Meijer CA, Le Haen PA, van Dijk RA, et al. Activator protein-1 (AP-1) signalling in human atherosclerosis: results of a systematic evaluation and intervention study. Clin Sci 2012;122:421-8.
133. Verborg W, Thomas H, Bissett D, et al. First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of action. Br J Cancer 2007;97:844-50.
134. Suchitha GP, Devasahayam Arokia Balaya R, Prasad TSK, Dagamajalu S. A signaling network map of lipoxin (LXA4): an anti-inflammatory molecule. Inflamm Res 2024;73:1099-106.
135. Liu M, Kang W, Hu Z, Wang C, Zhang Y. Targeting MyD88: therapeutic mechanisms and potential applications of the specific inhibitor ST2825. Inflamm Res 2023;72:2023-36.
136. Skrzycki M, Scibior-Bentkowska D, Podsiad M, Czeczot H. [Protein level of transcription factors AP-1 and NF-kappaB in selected human gastrointestinal tract tumors]. Pol Merkur Lekarski 2008;25:510-15.
137. Columbano A, Ledda-Columbano GM, Pibiri M, et al. Increased expression of c-fos, c-jun and LRF-1 is not required for in vivo priming of hepatocytes by the mitogen TCPOBOP. Oncogene 1997;14:857-63.
138. Innes H, Nahon P. Statistical perspectives on using hepatocellular carcinoma risk models to inform surveillance decisions. J Hepatol 2023;79:1332-7.
139. Xu F, Tong M, Tong CSW, et al. A combinatorial CRISPR-Cas9 screen identifies ifenprodil as an adjunct to sorafenib for liver cancer treatment. Cancer Res 2021;81:6219-32.
